HopeStage
Back to all studies
RecruitingNCT04366518

Rivastigmine or scopolamine for hallucinations in psychosis

About this titleRead the official source — NCT04366518
Medication studyAges 18–65United StatesSchizophrenia
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
New HavenSee all locations and recruitment
Study phase
Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 15, 2021
Recruitment status
Recruiting
Enrollment listed in the registry
35
Sponsor
Yale University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT04366518
Official title
Show the full official title

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Recruitment & locations

Currently recruiting

New Haven

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yale University, a university.

Does this study involve medication?

Yes. The study involves medication, including Rivastigmine Transdermal System, Scopolamine and Placebo Patch.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies